2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00259
    BM152054 213411-84-8
    BM152054 is a potent PPARgamma-activator. BM152054 can promote glucose utilization in peripheral tissues by enhancing insulin action.
    BM152054
  • HY-U00262
    ACT 178882 1007392-69-9
    ACT 178882 is a new Renin inhibitor with an IC50 of 1.4 nM.
    ACT 178882
  • HY-U00266
    Cefetrizole 65307-12-2
    Ceftezole is an α-Glucosidase inhibitor with an IC50 and a Ki of 2.1 μM and 0.578 μM, respectively.
    Cefetrizole
  • HY-U00270
    CP-319340(free base) 186390-35-2
    CP-319340 free base is a microsomal triglyceride transfer protein (MTP) inhibitor.
    CP-319340(free base)
  • HY-U00288
    Xanthine oxidase-IN-1 1071970-13-2
    Xanthine oxidase-IN-1 is a xanthine oxidase inhibitor extracted from patent WO2008126898A1, page 68, compound example 3, with an IC50 of 6.5 nM.
    Xanthine oxidase-IN-1
  • HY-U00329
    Implitapide Racemate 177277-99-5
    Implitapide Racemate is the racemate of Implitapide. Implitapide is a microsomal triglyceride transfer protein (MTP) inhibitor.
    Implitapide Racemate
  • HY-U00332
    Hydrocarbon chain derivative 1 300762-25-8
    Hydrocarbon chain derivative 1 is an active compound, with inhibitory activities against lipid synthesis.
    Hydrocarbon chain derivative 1
  • HY-U00353
    MCHR1 antagonist 1 391610-37-0
    MCHR1 antagonist 1 is a selective antagonist of melanin concentrating hormone-1 (MCH1) receptor, with a Kb of 1 nM and a Ki of 4 nM at human MCH1, and may be used to reduce the body mass.
    MCHR1 antagonist 1
  • HY-U00387
    CCK-A receptor inhibitor 1 137004-80-9
    CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binging IC50 of 340 nM.
    CCK-A receptor inhibitor 1
  • HY-U00391
    β3-AR agonist 2 340757-05-3
    β3-AR agonist 2 is a potent and selective β3-adrenergic receptor (β3-AR) agonist with an EC50 of 8 nM.
    β3-AR agonist 2
  • HY-U00395
    GPR40 Agonist 2 1147729-48-3
    GPR40 Agonist 2 is a GPR40 agonist that can be used in the research of diabetes, extracted from patent WO2009054479A1.
    GPR40 Agonist 2
  • HY-U00396
    MC-4R Agonist 1 455957-28-5
    MC-4R Agonist 1 is an agonist of human melanocortin-4 receptor (MC-4R), used in the research of obesity, diabetes, and sexual dysfunction.
    MC-4R Agonist 1
  • HY-U00397
    CB1 antagonist 1 890037-68-0
    CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.
    CB1 antagonist 1
  • HY-U00404
    Phentolamine Analogue 1 47142-51-8
    Phentolamine Analogue 1 is an analogue of phentolamine. Phentolamine is a nonselective alpha-adrenergic antagonist.
    Phentolamine Analogue 1
  • HY-U00411
    PSN-GK1 745051-61-0
    PSN-GK1 is a potent glucokinase activator with an EC50 of 0.13 μM.
    PSN-GK1
Cat. No. Product Name / Synonyms Application Reactivity